Arbutus Biopharma Corp. (NASDAQ:ABUS)’s share price was up 4.9% during trading on Friday . The company traded as high as $4.25 and last traded at $4.25, with a volume of 60,223 shares. The stock had previously closed at $4.05.

A number of equities research analysts have weighed in on the company. Zacks Investment Research raised Arbutus Biopharma Corp. from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Monday, April 25th. Chardan Capital downgraded Arbutus Biopharma Corp. from a “neutral” rating to a “sell” rating and reduced their target price for the company from $3.25 to $2.75 in a report on Friday, July 8th. Wedbush reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Arbutus Biopharma Corp. in a report on Wednesday, May 4th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $12.00 target price on shares of Arbutus Biopharma Corp. in a report on Thursday, May 5th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $10.96.

The company’s market capitalization is $229.97 million. The stock has a 50-day moving average of $3.72 and a 200 day moving average of $3.93.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last issued its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.20. On average, equities research analysts anticipate that Arbutus Biopharma Corp. will post ($1.49) earnings per share for the current year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.